VC
Value Add VC
⚡HomePulse⚡Helpful Apps📝Blog
← Pulse/Companies

Triveni Bio on Pulse

Biotech

The full thread of our Triveni Bio coverage — a running record of every development we've tracked, with the VC take on each.

2
Stories
2
With a headline figure
Jun 17, 2026
Since

Company Profile

Clinical-stage biotech developing genetics-informed antibody therapeutics for immunological and inflammatory diseases.

Founded 2023Watertown, Massachusetts$272M raised
Investors
Ascenta CapitalJanus Henderson InvestorsDeep Track Capital
See every investor we track →Everything connected to Triveni Bio →
Compare with
vs Jupiter Neurosciencesvs Ollin Biosciences

Coverage Timeline

newest first
  1. Jun 18, 2026FUNDINGTriveni Bio Raises $65M for Antibody Therapeutics in Immunology$65M→
  2. Jun 17, 2026FUNDINGTriveni Bio Raises $65M for Antibody-Based Immunology Therapeutics$65M→

All Coverage

FUNDING$65M

Triveni Bio Raises $65M for Antibody Therapeutics in Immunology

Triveni Bio raised $65 million, co-led by Ascenta Capital and Janus Henderson Investors, to advance antibody-based therapeutics for immunological and inflammatory diseases. The round is a reminder that biotech capital is still flowing to differentiated science even in an AI-dominated market.

Jun 18, 2026
FUNDING$65M

Triveni Bio Raises $65M for Antibody-Based Immunology Therapeutics

Triveni Bio raised $65 million co-led by Ascenta Capital and Janus Henderson to advance antibody-based therapeutics targeting immunological diseases. The round is part of a biotech rebound that's running alongside the AI-infrastructure boom rather than being crowded out by it.

Jun 17, 2026
@Trace_Cohen·t@nyvp.com